NICE recommends routine funding for Novartis’ Kisqali
Drug recommended as a second-line treatment for certain advanced breast cancers
Read More
Tag: Kisqali
New analysis shows survival benefit of Novartis’ Kisqali
In patients with liver metastases, Kisqali combination therapy cut the risk of death by 47% and 37% in two trials
Read More
Kisqali success continues with positive late-stage trial results
The success marks the second Phase III clinical trial in which Kisqali met overall survival.
Read More
NICE U-turn for Kisqali in breast cancer
NICE has recommended Novartis’ Kisqali just three months after its initial rejection.
Read More
Novartis’ Kisqali hits endpoints in Phase III breast cancer trial
Kisqali is the only CDK4/6 inhibitor to show superior overall survival in advanced breast cancer.
Read More
Novartis’ Kisqali hit with NICE rejection
The drug is typically used with fulvestrant to treat people with advanced breast cancer.
Read More
Kisqali wins speedy US breast cancer nod
Novartis’ Kisqali has been approved for breast cancer in the US less than one month after being filed with the US Food and Drug Administration.
Read More
SMC nod for Novartis’ Kisqali, MSD’s Keytruda
The Scottish Medicines Consortium (SMC has published new guidelines approving NHS funding for medicines for breast cancer and Hodgkin’s lymphoma.
Read More
US awards Novartis’ Kisqali ‘Breakthrough’ status
Novartis’ CDK4/6 inhibitor Kisqali has picked up Breakthrough status in the US as an initial endocrine-based treatment in certain patients with breast cancer.
Read More
Novartis’ Kisqali shows PFS benefit in premenopausal breast cancer
Novartis has unveiled Phase III data showing that partnering Kisqali with an endocrine therapy significantly prolonged progression-free survival compared to an endocrine therapy alone in patients with breast cancer.
Read More
NICE waves through breast cancer drugs following price deals
The National Institute for Health and Care Excellence is backing routine NHS funding for Pfizer’s Ibrance and Novartis’ Kisqali to treat certain forms of breast cancer, after the firms agreed to provide them at a reduced price under the new process for appraising medicines.
Read More
Novartis breast cancer drug Kisqali wins EU approval
Novartis has announced the launch of its new breast cancer drug Kisqali in the UK today following a green light from European regulators.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
